Commercial-stage biopharmaceutical company Rhythm Pharmaceuticals Inc (Nasdaq:RYTM) announced on Wednesday that the European Commission has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include children aged 2 to 6 years old.

IMCIVREE is indicated for patients with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.

It is the first authorised precision medicine in the European Union for control of hunger and treatment of obesity in adults and children, now as young as 2 years old, living with these conditions.